Molecular classification of patients with malignant melanoma for new therapeutic strategies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 25 ·No. 16 ·2007-06-01 ·Pages e20-1

Palmieri G, Casula M, Ascierto PA, Tanda F, Cossu A

Abstract

暂无摘要

MeSH Terms

Combined Modality Therapy Dacarbazine/administration & dosage Extracellular Signal-Regulated MAP Kinases/physiology Humans Melanoma/drug therapy Oligonucleotides, Antisense/administration & dosage Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors,genetics Signal Transduction Skin Neoplasms/drug therapy Thionucleotides/administration & dosage

Chemicals

Oligonucleotides, Antisense Proto-Oncogene Proteins c-bcl-2 Thionucleotides Dacarbazine oblimersen Extracellular Signal-Regulated MAP Kinases

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Palmieri Giuseppe

Casula Milena

Ascierto Paolo A

Tanda Francesco

Cossu Antonio

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

1527-7755

DOI

10.1200/JCO.2007.11.0965

Published

2007-06-01

Pages

e20-1

Language

English

Region

United States

NLM ID

8309333

Subset

Corrections

CommentOn

PMID: 16966688

External Links

PubMed source DOI: 10.1200/JCO.2007.11.0965 View journal details

Analysis Services

Molecular classification of patients with malignant melanoma for new therapeutic strategies.

Contact

WeChat Official Account